Madeline K. Elsey , Nina M. Beltran , Katherine M. Serafine
{"title":"Eating a ketogenic diet enhances sensitivity of rats to the effects of methamphetamine, but not dopamine D2/D3 receptor agonist quinpirole","authors":"Madeline K. Elsey , Nina M. Beltran , Katherine M. Serafine","doi":"10.1016/j.pbb.2025.174072","DOIUrl":null,"url":null,"abstract":"<div><div>High fat diets are linked to several negative health consequences in humans including disrupted insulin signaling, and research with rodents has demonstrated that these diets can also increase individual sensitivity to drugs that act on dopamine systems. Since ketogenic diets have different effects on weight and insulin signaling than traditional high fat diets, it was hypothesized that a ketogenic diet (high in fat but very low in carbohydrates) might not increase sensitivity of rats to dopaminergic drugs. To test this hypothesis rats eating standard chow (17 % kcal from fat), high fat chow (60 % kcal from fat), or ketogenic chow (90.5 % kal from fat) were tested once weekly with quinpirole [0.0032–0.32 mg/kg, intraperitoneally (i.p.)] or methamphetamine (0.1–3.2 mg/kg, i.p.) using a cumulative dosing procedure. Consistent with previous reports, eating high fat chow enhanced sensitivity of rats to the behavioral effects of quinpirole and methamphetamine. While eating a ketogenic chow did not impact sensitivity to quinpirole, rats eating ketogenic chow were more sensitive than rats eating standard chow to methamphetamine-induced locomotion, but only at the largest cumulative dose tested. These results suggest that traditional high fat diets and ketogenic diets might produce similar, but non-identical effects on sensitivity to the behavioral effects of dopaminergic drugs.</div></div>","PeriodicalId":19893,"journal":{"name":"Pharmacology Biochemistry and Behavior","volume":"255 ","pages":"Article 174072"},"PeriodicalIF":2.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Biochemistry and Behavior","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091305725001194","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
High fat diets are linked to several negative health consequences in humans including disrupted insulin signaling, and research with rodents has demonstrated that these diets can also increase individual sensitivity to drugs that act on dopamine systems. Since ketogenic diets have different effects on weight and insulin signaling than traditional high fat diets, it was hypothesized that a ketogenic diet (high in fat but very low in carbohydrates) might not increase sensitivity of rats to dopaminergic drugs. To test this hypothesis rats eating standard chow (17 % kcal from fat), high fat chow (60 % kcal from fat), or ketogenic chow (90.5 % kal from fat) were tested once weekly with quinpirole [0.0032–0.32 mg/kg, intraperitoneally (i.p.)] or methamphetamine (0.1–3.2 mg/kg, i.p.) using a cumulative dosing procedure. Consistent with previous reports, eating high fat chow enhanced sensitivity of rats to the behavioral effects of quinpirole and methamphetamine. While eating a ketogenic chow did not impact sensitivity to quinpirole, rats eating ketogenic chow were more sensitive than rats eating standard chow to methamphetamine-induced locomotion, but only at the largest cumulative dose tested. These results suggest that traditional high fat diets and ketogenic diets might produce similar, but non-identical effects on sensitivity to the behavioral effects of dopaminergic drugs.
期刊介绍:
Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided.